Medifast (MED) Defended at DA Davidson
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Medifast (MED) Reports In-Line Q3 EPS, Offers Guidance
November 6, 2018 4:13 PM ESTMedifast (NYSE: MED) reported Q3 EPS of $1.14, in-line with the analyst estimate of $1.14. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $125.81 million.
GUIDANCE:
Medifast sees Q4 2018 EPS of $1.15-$1.20, versus the consensus of $1.16. Medifast sees Q4 2018... More
